NASDAQ:ATHE Alterity Therapeutics Q4 2026 TU Earnings Report $4.47 -0.10 (-2.19%) Closing price 08/25/2026 04:00 PM EasternExtended Trading$4.52 +0.05 (+1.12%) As of 08/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alterity Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.12Beat/MissN/AOne Year Ago EPSN/AAlterity Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.32 millionBeat/MissN/AYoY Revenue GrowthN/AAlterity Therapeutics Announcement DetailsQuarterQ4 2026 TUDate8/28/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Alterity Therapeutics Earnings HeadlinesAlterity Therapeutics (ATHE) Projected to Release Quarterly Earnings on FridayAugust 21, 2026 | americanbankingnews.comAnalysts Set Alterity Therapeutics Limited - Sponsored ADR (NASDAQ:ATHE) Price Target at $12.67August 16, 2026 | americanbankingnews.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. | Paradigm Press (Ad)Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434August 12, 2026 | globenewswire.comAlterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth ConferenceAugust 6, 2026 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate UpdateJuly 30, 2026 | finanznachrichten.deSee More Alterity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alterity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alterity Therapeutics and other key companies, straight to your email. Email Address About Alterity TherapeuticsAlterity Therapeutics (NASDAQ:ATHE) is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation. Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials. Another key program, PBT434, is an oral small molecule aimed at modulating metal-mediated oxidative stress, currently in early-stage development for Parkinson’s disease and related disorders. Originally established in 1998 as Neuren Pharmaceuticals, the company rebranded to Alterity Therapeutics in 2023 to reflect its distinct focus on neurodegenerative conditions. Headquartered in Australia, Alterity conducts global clinical studies across North America, Europe and Australia, leveraging strategic partnerships to advance its pipeline toward regulatory milestones.View Alterity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DICK's Sporting Goods Faces Pain Now for a Bigger PrizeStoneX: Too Far Too Fast?Pathward’s Credit Scare Tests Its Comeback StoryNVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to WatchBeyond Big Tech: 3 Non-Tech Earnings Winners to WatchThe Bull Case for D-Wave After a Disappointing Earnings SeasonVisa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Upcoming Earnings Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
